Suven Life Sciences shares zoom 20% on securing three product patents
At the NSE, it soared 19.99% to Rs 209.15. Neurodegenerative diseases include Alzheimer's disease, Schizophrenia and Parkinson's disease.
By PTI | Updated:
MUMBAI: Shares of pharmaceutical firm Suven Life Sciences surged 20 per cent today as the company has been granted three product patents one each by South Korea, China and Canada for drug used in the treatment of neurodegenerative diseases.
The pharma firm's scrip ended at Rs 208.95, up 19.98 per cent on the BSE.
At the NSE, it soared 19.99 per cent to Rs 209.15. Neurode generative diseases include Alzheimer's disease, Schizophrenia and Parkinson's disease.
In a BSE filing the company had on Wednesday said it has been granted "one product patent from South Korea, one product patent from China and one product patent from Canada corresponding to the new chemical entities for the treatment of disorders associated with neurodegenerative diseases".
These patents are valid through 2029, 2029 and 2031, respectively, the company had said.
The pharma firm's scrip ended at Rs 208.95, up 19.98 per cent on the BSE.
At the NSE, it soared 19.99 per cent to Rs 209.15. Neurode generative diseases include Alzheimer's disease, Schizophrenia and Parkinson's disease.
In a BSE filing the company had on Wednesday said it has been granted "one product patent from South Korea, one product patent from China and one product patent from Canada corresponding to the new chemical entities for the treatment of disorders associated with neurodegenerative diseases".
These patents are valid through 2029, 2029 and 2031, respectively, the company had said.
Too busy to trade in stocks? Invest in Mutual Funds with ET Money!
Bookmark or read stories offline -
Download ET Markets APP
Download ET Markets APP
ADVERTISEMENT
